| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 68.0 | 61.0 |
| Gross profit | 48.7 | 46.0 |
| Profit before tax | 19.7 | 22.6 |
| Net income | 15.0 | 17.4 |
| EPS (diluted, $ a share) | $0.65 | $0.75 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -13.5% |
|---|---|
| Revenue, year on year | +11.3% |
| Gross margin | 71.7% |
| Operating margin | 26.0% |
10-Q filed with the SEC, NASDAQ: LMAT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lemaitre Vascular Inc: key numbers
- Share price
- $77.01Close, Nov 16
- Market cap
- $1.76B
- Shares outstanding
- 22.88MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lemaitre Vascular Inc
All →Lemaitre Vascular Financial Results
LeMaitre Vascular reported Q3 2026 sales of $68.0 million, an 11% increase driven by strong performance in grafts and shunts. The company also announced the $19.2 million acquisition of vascular assets from B. Braun and declared a quarterly dividend of $0.25 per share.
- Term
- Q3 2026
“We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force.”
George LeMaitre, Chairman/CEO
Lemaitre Vascular Leadership Change
David B. Roberts notified the company of his intent to retire as President effective December 31, 2026, after 29 years of executive service. Mr. Roberts will continue to serve on the Board of Directors following his retirement as an employee.